HBC(SH:603077) Xin Lang Cai Jing·2026-02-26 01:29Core Viewpoint - Hebang Bio experienced a significant stock price increase of 9.92% on February 25, with a trading volume of 1 billion yuan, indicating strong market interest and activity in the company's shares [1]. Financing Summary - On February 25, Hebang Bio had a financing buy-in amount of 170 million yuan, with a net financing purchase of 111 million yuan after repayments of 58.72 million yuan [1]. - The total financing and margin trading balance for Hebang Bio reached 673 million yuan as of February 25, with the financing balance of 664 million yuan accounting for 2.61% of the circulating market value, indicating a high level compared to the past year [1]. - In terms of securities lending, Hebang Bio had a short selling of 420,500 shares on February 25, with a total selling amount of approximately 1.21 million yuan, and a remaining short selling volume of 3.0033 million shares, which is also at a high level compared to the past year [1]. Company Overview - Hebang Bio, established on August 1, 2002, and listed on July 31, 2012, is located in Niuhua Village, Wutongqiao District, Leshan City, Sichuan Province [1]. - The company's main business includes the manufacturing of pesticides and pesticide intermediates, fine chemical products, intelligent glass, special glass, and the production of soda ash and ammonium chloride, as well as the development of salt and phosphate mines [1]. - The revenue composition of Hebang Bio is as follows: chemical products account for 85.89%, photovoltaic glass and other products 17.61%, mineral products 6.74%, and other businesses 5.02% [1]. Financial Performance - As of September 30, 2025, Hebang Bio reported a total revenue of 5.927 billion yuan for the first nine months, reflecting a year-on-year decrease of 13.02% [2]. - The net profit attributable to the parent company was 93.1085 million yuan, showing a significant year-on-year decline of 57.93% [2]. Shareholder Information - As of September 30, 2025, the number of shareholders for Hebang Bio was 196,500, a decrease of 1.99% from the previous period, while the average circulating shares per person increased by 2.03% to 44,939 shares [2]. - The top ten circulating shareholders include new entrants such as Penghua CSI Sub-Segment Chemical Industry Theme ETF and Everbright Prudential Credit Enhanced Bond A, indicating changes in institutional holdings [3].